HIV Genotyping Drug Resistance Assays Should Be Downclassified - Panel
This article was originally published in The Gray Sheet
Executive Summary
Downclassification of HIV genotyping drug resistance assays with special controls would serve the public health interest and "be of use to every AIDS patient in the lifetime of their illness," FDA staffers asserted Sept. 17 before the Blood Products Advisory Committee.
You may also be interested in...
VGI Awaiting 510(k) Clearance For Trugene; FDA Drafts Guidance Document
Visible Genetics, Inc.(VGI) is confident that the clinical data for the company's Trugene HIV-1 genotyping test meets the standards set forth in an August FDA Center for Biologics Evaluation and Research (CBER) special controls draft guidance for in vitro HIV drug resistance genotype assays.
VGI Awaiting 510(k) Clearance For Trugene; FDA Drafts Guidance Document
Visible Genetics, Inc.(VGI) is confident that the clinical data for the company's Trugene HIV-1 genotyping test meets the standards set forth in an August FDA Center for Biologics Evaluation and Research (CBER) special controls draft guidance for in vitro HIV drug resistance genotype assays.
VGI Trugene HIV-1 Test Downclassification Petition Anticipated By August
Visible Genetics, Inc. plans to submit a petition to FDA by August seeking classification of its Trugene HIV-1 genotyping test and OpenGene DNA sequencing system as Class II following FDA's rejection of a September 2000 510(k) submission.